Anifrolumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), NYE METODER (Norway) and PHARMAC (New Zealand), among others, recommended or restricted anifrolumab, while AOTMIT (Poland) and HAS (France) did not recommend it.
The record spans 4.1 years, opening at NICE (England) on 8 Jun 2022 and running to 2026.
CIPM (Spain) changed its position: not recommended on 2 Feb 2023, recommended by 28 Apr 2026, after a resubmission.
No assessment is on file from SMC (Scotland) and AWMSG (Wales), each among the eight highest-volume agencies here.
Not every gap is a refusal: for anifrolumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 12 of 16 records date from 2023 or later.
4 of these 16 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
NICE (England) was first to assess anifrolumab, on 8 Jun 2022; ZIN (Netherlands) did not open a file until 28 May 2026 — a wide spread of 3.9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
3 of the 11 agencies here assessed anifrolumab more than once, PBAC (Australia) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for anifrolumab.
The full ledger for anifrolumab reads 8 recommended, 5 not recommended, 1 restricted and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 28 May 2026 | Advies - vergoed anifrolumab subcutaan (Saphnelo®) voor de behandeling van systemische lupus erythematosus | reimbursed | source |
| TLV (Sweden) | 26 May 2026 | Saphnelo ingår i högkostnadsskyddet med generell subvention | general subsidy | source |
| NYE METODER (Norway) | 26 Apr 2026 | Tilleggsbehandling av voksne med moderat til alvorlig aktiv, auto-antistoffpositiv systemisk lupus erythematosus (SLE), … | introduced | source |
| PHARMAC (New Zealand) | 13 Nov 2025 | Systemic Lupus Erythematosus (SLE), SLEDAI-2K ≥10, following triple therapy | PTAC advice: Low | source |
| CIPM (Spain) | 2 Feb 2023 | SECRETARIA DE ESTADO DE SANIDAD 33 MINISTERIO DE SANIDAD MINISTERIO DE SANIDAD Indicación terapéutica autorizada: Saphne… | not financed by the SNS (financed 2026-04) | source |
11 further decisions for anifrolumab, across 8 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 16 decisions for anifrolumab from 11 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.